NMN
Nicotinamide Mononucleotide · NAD+ precursor
NAD⁺ precursor: more cellular energy and a possible anti-aging effect.
Grado
B
Moderata
- Classe
- Cellular metabolism
- Uso principale
- NAD⁺ and metabolic support
- Forza evidenza
- medium
- Ultima revisione
- 2024-11-15
Cosa promette
NAD⁺ precursor: more cellular energy and a possible anti-aging effect.
Cosa dice l'evidenza
Phase I/II human trials consistently raise blood NAD⁺ (+40–80%), but with small samples, short follow-up and surrogate outcomes. Hard clinical endpoints are not yet demonstrated.
Studi chiave
- [1]
Effect of 12-week NMN supplementation in older adults · RCT
Blood NAD⁺ raised; gait speed improved in a subset. n=25.
PMID 35995051 ↗ - [2]
NMN supplementation and metabolic parameters · RCT
Positive metabolic signals, limited sample.
PMID 34930279 ↗ - [3]
Tissue NAD⁺ decline with age · preclinical
Rationale: tissue NAD⁺ falls 40–60% with age.
PMID 33394883 ↗
Meccanismo
Direct precursor of NAD⁺ in the salvage pathway; NAD⁺ is a cofactor of sirtuins and PARPs, involved in DNA repair and metabolic regulation.
Sicurezza
Good short-term tolerability in available RCTs: no severe adverse events reported. Long-term safety data are lacking.
Contesto dosaggio
In studies: 250–900 mg/day for 8–24 weeks. Higher doses did not show proportionally greater benefit.
Nota dal campo
We follow NMN trial by trial and we know how it's sold: the NAD⁺ numbers are real, but the leap 'more NAD⁺ = live better' is not yet proven in humans. Hence grade B.